Sanofi to purchase Kymab and add OX40L monoclonal antibody to its pipeline
Sanofi is set to acquire Cambridge, UK-headquartered Kymab and thereby add KY1005 to its pipeline, a human monoclonal antibody targeting
Read moreSanofi is set to acquire Cambridge, UK-headquartered Kymab and thereby add KY1005 to its pipeline, a human monoclonal antibody targeting
Read moreDrug regulators in the United Kingdom have approved a second COVID-19 vaccine for emergency use today, for the active immunisation
Read moreBioNTech and InstaDeep have entered into an agreement to establish a joint AI Innovation Lab in London, United Kingdom and
Read moreAstraZeneca announced today, that interim trial data has shown it’s COVID-19 vaccine candidate AZD1222, developed in collaboration with the University
Read morePhenomic AI, a Canadian biotechnology company that uses an AI/ML platform for targeting the tumor stroma, has launched with $6
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreJanssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read moreSwiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read moreNestlé’s nutritional science brand Nestlé Health Science (NHSc) furthers efforts of food allergy prevention through the acquisition of California-based biopharmaceutical
Read moreEli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read more